Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

Drug-free approach shown to reduce depression relapse among new and expectant moms (opens in a new tab)

medicalxpress.com · 2026-10-22

Short answerEvidenceSource

Short answer

Mixed

Mixed.

2 claims go further than the study. One other point was not covered by the paper.

  • 3 supported
  • 2 overstated
  • 1 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

Two of six claims overstate the study. Three of six check out. One claim the study doesn't address.

  • 3 supported
  • 2 overstated
  • 1 not covered
Open claim evidence
3
Source paper

Source layer

The 2 papers the story cites

Source study separated from background citations.

The research anchor for the report.

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

6 claims in this story

Showing all 6 claimsChoose a verdict to focus the list.

Claim 1 of 6OverstatedOn average, those in the MMB for Moms group were 26% less likely to experience a return of their depression, and most also had significant protection from anxiety and stress symptoms during the program.View evidenceHide evidence

As stated26% less likely

Why this verdict

The 26% lower relapse-risk statement is supported by the reported HR of 0.74 for depressive relapse through 6 months postpartum. However, the claim goes beyond the abstract-level paper evidence by saying most participants had significant protection from anxiety and stress symptoms. The supplied profile reports PHQ-9 depressive symptom burden, not anxiety or stress outcomes, and the depressive symptom advantage was limited to the 12-week intervention phase, with no significant difference across the full trial period.

1

Study evidence

MMB for Moms plus usual care reduced the risk of depressive relapse through 6 months postpartum compared with usual care alone.Hazard ratio 0.74 (95% CI 0.56–0.99); p=0.045; adjusted FDR p=0.045. Relapse counts: 81/249 (33%) MMB vs 111/251 (44%) usual care.

“This single-blind, randomised clinical trial was done across the USA”
2

Study evidence

MMB for Moms produced a greater reduction in PHQ-9 depressive symptom burden during the 12-week intervention phase compared with usual care.MMB mean decrease 0.75 (SE 0.13) vs usual care mean decrease 0.31 (SE 0.13) during the 12-week intervention phase; reported as statistically significant.

“Primary outcomes were reduction in depressive relapse risk and symptom burden, assessed using ... Patient Health Questionaire-9”
Claim 2 of 6OverstatedThe article says the program is intended to prevent relapse rather than treat perinatal depression, and that it may serve as an adjunct or alternative to medication depending on individual needs and preferences.View evidenceHide evidence

Why this verdict

The relapse-prevention framing is supported because the trial enrolled euthymic pregnant women with recurrent depression and assessed prevention of depressive relapse rather than treatment of active perinatal depression. But the medication framing is overstated: the trial tested MMB for Moms added to usual care in women on recent or current antidepressant medication, so the abstract-level evidence supports an adjunct-to-usual-care interpretation more than an alternative-to-medication interpretation.

1

Study evidence

MMB for Moms plus usual care reduced the risk of depressive relapse through 6 months postpartum compared with usual care alone.Hazard ratio 0.74 (95% CI 0.56–0.99); p=0.045; adjusted FDR p=0.045. Relapse counts: 81/249 (33%) MMB vs 111/251 (44%) usual care.

“This single-blind, randomised clinical trial was done across the USA”
Claim 3 of 6Not coveredThe program, Mindful Mood Balance for Moms (MMB for Moms), teaches mindfulness techniques and cognitive behavioral skills through audio-guided practices, videos and advice from peers and professionals.View evidenceHide evidence

Why this verdict

The abstract-level profile supports that MMB for Moms is a web-based mindfulness-based cognitive therapy programme customized for perinatal women. It does not provide enough detail to verify the specific delivery components claimed by the story, such as audio-guided practices, videos, or advice from peers and professionals.

1

Study evidence

MMB for Moms plus usual care reduced the risk of depressive relapse through 6 months postpartum compared with usual care alone.Hazard ratio 0.74 (95% CI 0.56–0.99); p=0.045; adjusted FDR p=0.045. Relapse counts: 81/249 (33%) MMB vs 111/251 (44%) usual care.

“This single-blind, randomised clinical trial was done across the USA”
2

Study evidence

MMB for Moms produced a greater reduction in PHQ-9 depressive symptom burden during the 12-week intervention phase compared with usual care.MMB mean decrease 0.75 (SE 0.13) vs usual care mean decrease 0.31 (SE 0.13) during the 12-week intervention phase; reported as statistically significant.

“Primary outcomes were reduction in depressive relapse risk and symptom burden, assessed using ... Patient Health Questionaire-9”
Claim 4 of 6SupportedA free, online program developed by University of Colorado Boulder researchers was shown to reduce the risk of depression relapse by double digits among new moms and moms-to-be who had struggled with depression before.View evidenceHide evidence

As stateddouble digits

Why this verdict

The core headline claim is supported by the abstract-level RCT evidence: MMB for Moms plus usual care lowered depressive relapse risk versus usual care through 6 months postpartum, with HR 0.74, equivalent to about 26% lower hazard, and relapse counts of 33% vs 44%. The population had recurrent depression and was followed through pregnancy/postpartum. The abstract profile supports the program as web-based, but does not independently verify the story's non-scientific details that it was free or developed by CU Boulder researchers.

1

Study evidence

MMB for Moms plus usual care reduced the risk of depressive relapse through 6 months postpartum compared with usual care alone.Hazard ratio 0.74 (95% CI 0.56–0.99); p=0.045; adjusted FDR p=0.045. Relapse counts: 81/249 (33%) MMB vs 111/251 (44%) usual care.

“This single-blind, randomised clinical trial was done across the USA”
Claim 5 of 6SupportedThe findings came from a national study of 500 expectant mothers and were published in The Lancet Public Health.View evidenceHide evidence

As stated500 expectant mothers

Why this verdict

The profile supports that the findings came from a US-wide randomized clinical trial with 500 pregnant participants. The profile is consistent with a national study of expectant mothers, though the supplied abstract-level evidence does not independently document the journal venue beyond the paper profile context.

1

Study evidence

MMB for Moms plus usual care reduced the risk of depressive relapse through 6 months postpartum compared with usual care alone.Hazard ratio 0.74 (95% CI 0.56–0.99); p=0.045; adjusted FDR p=0.045. Relapse counts: 81/249 (33%) MMB vs 111/251 (44%) usual care.

“This single-blind, randomised clinical trial was done across the USA”
2

Study evidence

MMB for Moms produced a greater reduction in PHQ-9 depressive symptom burden during the 12-week intervention phase compared with usual care.MMB mean decrease 0.75 (SE 0.13) vs usual care mean decrease 0.31 (SE 0.13) during the 12-week intervention phase; reported as statistically significant.

“Primary outcomes were reduction in depressive relapse risk and symptom burden, assessed using ... Patient Health Questionaire-9”
Claim 6 of 6SupportedIn a randomized, controlled trial, half of the participants received MMB for Moms for 12 weeks with coaching check-ins, while the other half continued usual care; relapse was assessed up to six months postpartum.View evidenceHide evidence

As stated12 weeks; up to six months postpartum

Why this verdict

The trial was a two-arm randomized controlled trial with 249 participants assigned to MMB for Moms plus usual care and 251 to usual care alone, followed to 6 months postpartum. The profile supports the 12-week intervention phase and postpartum relapse assessment. The specific detail of coaching check-ins is not verifiable from the abstract-level profile, but the main trial-design description is supported.

1

Study evidence

MMB for Moms plus usual care reduced the risk of depressive relapse through 6 months postpartum compared with usual care alone.Hazard ratio 0.74 (95% CI 0.56–0.99); p=0.045; adjusted FDR p=0.045. Relapse counts: 81/249 (33%) MMB vs 111/251 (44%) usual care.

“This single-blind, randomised clinical trial was done across the USA”
2

Study evidence

MMB for Moms produced a greater reduction in PHQ-9 depressive symptom burden during the 12-week intervention phase compared with usual care.MMB mean decrease 0.75 (SE 0.13) vs usual care mean decrease 0.31 (SE 0.13) during the 12-week intervention phase; reported as statistically significant.

“Primary outcomes were reduction in depressive relapse risk and symptom burden, assessed using ... Patient Health Questionaire-9”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • The trial population was narrower than 'moms with prior depression': participants were pregnant, euthymic women with recurrent depression who were on recent or current antidepressant medication.

    The story mentions a history of depression and relapse prevention, but it does not clearly convey the euthymic-at-baseline requirement or the recent/current antidepressant-medication criterion. This matters for interpreting generalizability and for claims about the program as an alternative to medication.

    From Pragmatic randomized clinical trial (two-arm, single-blind); Pragmatic randomized clinical trial (two-arm), single-blind

  • The symptom-burden finding was specific to depressive symptoms measured by PHQ-9: improvement was greater during the 12-week intervention phase but not across the full trial period to 6 months postpartum.

    The story frames secondary symptom benefits as anxiety and stress protection, which is not reflected in the supplied abstract profile. It also does not clearly state the paper's important qualification that the depressive-symptom advantage was not present across the full trial period.

    From Pragmatic randomized clinical trial (two-arm), single-blind outcome assessment

  • The intervention was tested as an addition to usual care, not as a standalone replacement for antidepressant medication.

    The story does state usual care in the trial description, but its caveat that the program may be an alternative to medication is not supported by the abstract-level evidence, especially because the trial population involved women on recent or current antidepressants.

    From Pragmatic randomized clinical trial (two-arm, single-blind)

  • Follow-up was incomplete, with assessment completion of 77% at 3 months and 78% at 6 months postpartum.

    The story's listed caveats mention uncertainty about duration of benefits but do not mention incomplete assessment completion, which is a material limitation in interpreting trial estimates.

    From Pragmatic randomized clinical trial (two-arm, single-blind); Pragmatic randomized clinical trial (two-arm), single-blind

2 things the story did carry across
  • The central study was a two-arm, single-blind pragmatic randomized clinical trial across the USA comparing MMB for Moms plus usual care with usual care alone in 500 pregnant participants.
  • MMB for Moms reduced depressive relapse risk through 6 months postpartum compared with usual care, with HR 0.74, 95% CI 0.56–0.99, p=0.045, and relapse counts of 81/249 vs 111/251.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

2

Evidence read

study summary

Lead result

human in vivo

1Lead resulthuman in vivoEvaluate whether adding the Mindful Mood Balance (MMB) for Moms web-based mindfulness-based cognitive therapy programme to usual care reduces risk of perinatal depressive relapse vs usual care alone (through 6 months postpartum).Pragmatic randomized clinical trial (two-arm, single-blind)Expand

In plain English

Pragmatic, two-arm, single-blind randomized clinical trial across the USA comparing a web-based mindfulness-based cognitive therapy programme (Mindful Mood Balance for Moms) plus usual care versus usual care alone in euthymic pregnant women with recurrent depression on recent or current antidepressant medication; primary endpoints were time-to-event depressive relapse (assessed by the Mini International Neuropsychiatric Interview) through 6 months postpartum and depressive symptom burden (PHQ-9). In the intention-to-treat sample (n=500; 249 MMB, 251 usual care) MMB for Moms reduced risk of depressive relapse through 6 months postpartum (81/249 vs 111/251; hazard ratio 0.74, 95% CI 0.56–0.99; p=0.045, adjusted FDR p=0.045). MMB for Moms was associated with greater reduction in PHQ-9 symptom burden during the 12-week intervention phase (mean decrease 0.75 [SE 0.13] vs 0.31 [SE 0.13]) but not across the full trial period (mean decrease 0.61 [SE 0.18] vs 0.54 [SE 0.17]).

Key findings

  • MMB for Moms plus usual care reduced the risk of depressive relapse through 6 months postpartum compared with usual care alone.Hazard ratio 0.74 (95% CI 0.56–0.99); p=0.045; adjusted FDR p=0.045. Relapse counts: 81/249 (33%) MMB vs 111/251 (44%) usual care.
  • MMB for Moms was associated with a greater reduction in depressive symptom burden (PHQ-9) during the 12-week intervention phase but not across the full trial period to 6 months postpartum.Intervention phase mean PHQ-9 decrease: 0.75 (SE 0.13) MMB vs 0.31 (SE 0.13) usual care. Full trial period mean decreases: 0.61 (SE 0.18) MMB vs 0.54 (SE 0.17) usual care.
“This single-blind, randomised clinical trial was done across the USA”
2human in vivoEvaluate whether MMB for Moms reduces depressive symptom burden (PHQ-9) vs usual care, including phase-specific effects (eg, during the 12-week intervention) and across the full trial period.Pragmatic randomized clinical trial (two-arm), single-blind outcome assessmentExpand

In plain English

In this two-arm, single-blind pragmatic randomized trial of pregnant women with recurrent depression on antidepressants, the web-based Mindful Mood Balance (MMB for Moms) programme reduced self-reported depression symptom burden (PHQ-9) more than usual care during the 12-week intervention phase but showed no clear advantage across the full trial period to 6 months postpartum.

Key findings

  • MMB for Moms produced a greater reduction in PHQ-9 depressive symptom burden during the 12-week intervention phase compared with usual care.MMB mean decrease 0.75 (SE 0.13) vs usual care mean decrease 0.31 (SE 0.13) during the 12-week intervention phase; reported as statistically significant.
  • Across the full trial period (baseline to 6 months postpartum), there was no significant difference between MMB for Moms and usual care in PHQ-9 symptom change.MMB mean decrease 0.61 (SE 0.18) vs usual care mean decrease 0.54 (SE 0.17) across the full trial period; reported as not significant.
“Primary outcomes were reduction in depressive relapse risk and symptom burden, assessed using ... Patient Health Questionaire-9”
What this piece can’t prove

3 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Open the paper in Tessa

Outcomes of Mindful Mood Balance for Moms, online mindfulness-based cognitive therapy for perinatal depressive relapse prevention in the USA: a two-arm, single-blind, pragmatic randomised clinical trial

The Lancet. Public health · 2026

Deep dive in Tessa (opens in a new tab)Source record (opens in a new tab)

Why this one

Near certain

NewsLink found the paper. Tessa is where you inspect it deeply.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 39 candidate papers

Selected

Outcomes of Mindful Mood Balance for Moms, online mindfulness-based cognitive therapy for perinatal depressive relapse prevention in the USA: a two-arm, single-blind, pragmatic randomised clinical trial

The Lancet. Public Health · 2026 · PubMed, Europe PMC, Crossref

Tessa (opens in a new tab)Source (opens in a new tab)

And 33 more candidates considered.